Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors

Available (expanded access)

Conditions studied: Advanced Solid Tumors, Cholangiocarcinoma

In brief

This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors

Key facts

Study ID

NCT06370013

Run by

TransThera Sciences (Nanjing), Inc.

Last updated by the study team

2024-04-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is currently enrolled in a pre-defined TransThera-sponsored parent study and is receiving tinengotinib as a single agent.
• Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.

You may not qualify if…

• Subject has been permanently discontinued from tinengotinib in the parent protocol for any reason other than enrollment in the Rollover study
• Subject does not meet the criteria specified in the parent protocol for continued treatment on study.

Where it is running

• University of Chicago Medical Center — Chicago, Illinois, United States
• Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• UW Carbone Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.